Brown, Lisle/Cummings, Inc. Bristol Myers Squibb CO Transaction History
Brown, Lisle/Cummings, Inc.
- $329 Billion
- Q3 2024
A detailed history of Brown, Lisle/Cummings, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Brown, Lisle/Cummings, Inc. holds 23,315 shares of BMY stock, worth $1.3 Million. This represents 0.37% of its overall portfolio holdings.
Number of Shares
23,315
Previous 21,313
9.39%
Holding current value
$1.3 Million
Previous $885 Million
36.29%
% of portfolio
0.37%
Previous 0.29%
Shares
12 transactions
Others Institutions Holding BMY
# of Institutions
2,444Shares Held
1.51BCall Options Held
29.7MPut Options Held
32.1M-
Vanguard Group Inc Valley Forge, PA187MShares$10.4 Billion0.15% of portfolio
-
Black Rock Inc. New York, NY159MShares$8.85 Billion0.15% of portfolio
-
State Street Corp Boston, MA91.4MShares$5.1 Billion0.17% of portfolio
-
Jpmorgan Chase & CO New York, NY74.6MShares$4.16 Billion0.27% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA59.1MShares$3.29 Billion0.47% of portfolio
About BRISTOL MYERS SQUIBB CO
- Ticker BMY
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 2,126,160,000
- Market Cap $119B
- Description
- Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...